背景:先前的研究表明,维生素K对于预防各种慢性疾病至关重要。叶醌是维生素K的主要膳食和循环形式。然而,有关血浆苯醌与全因死亡率之间关联的数据有限.
目的:本研究旨在评估血浆页醌与全因死亡风险之间的关系,并研究一些潜在的混杂因素。
方法:这项研究是对RCT的事后分析,采用病例对照设计。参与者在基线时必须患有高血压。研究开始于5月19日,2008年,中位随访时间为4.5年。共有604例死亡病例和604例对照年龄相匹配,性别,治疗组,和研究地点被纳入本研究。使用条件或无条件逻辑回归计算全因死亡率的赔率比(OR)和95%置信区间(CIs)。在没有或没有调整相关协变量的情况下,分别。通过液相色谱-串联四极杆质谱(LC-MS/MS)测量页醌的浓度。
结果:苯醌的平均和中值水平分别为1.62nmol/L和0.89nmol/L,分别。在控制潜在的混杂因素后,对数转化血浆苯醌与全因死亡率之间存在显著负相关(每增加1个单位-OR:0.79;95%CI:0.66,0.95)。此外,血浆页醌与全因死亡风险的相关性因体重指数(BMI)而异(<25kg/m2与≥25kg/m2相比,P-交互作用=0.004).在BMI较高的参与者中观察到随着苯醌浓度的增加风险的显着趋势(每增加1个单位-OR:0.71;95%CI:0.56,0.90;P=0.004)。在BMI<25kg/m2的人群中,苯醌与全因死亡风险之间没有显着相关性。
结论:在中国高血压患者中,基线血浆苯醌与全因死亡率之间存在显著负相关,尤其是BMI较高的人群。
Previous studies have revealed that vitamin K is essential for preventing various chronic diseases.
Phylloquinone is the primary dietary and circulating form of vitamin K. However, data concerning the association between plasma
phylloquinone and all-cause mortality are limited.
This study aimed to evaluate the association between plasma phylloquinone and risk of all-cause mortality and examine some potential confounders.
This study is a post hoc analysis of the RCT and a nested, case-control design was used. Enrolled participants had to have hypertension at baseline. Study initiation was 19 May, 2008, and the median follow-up was 4.5 y. A total of 604 mortality cases and 604 controls matched for age, sex, treatment group, and study site were included in this study. Odds ratios (OR) and 95% confidence intervals (CIs) of all-cause mortality were calculated using conditional or unconditional logistic regression, without or with adjusting for pertinent covariates, respectively. The concentration of phylloquinone was measured by liquid chromatography-tandem quadrupole mass spectrometry (LC-MS/MS).
The mean and median
phylloquinone levels were 1.62 nmol/L and 0.89 nmol/L, respectively. There was a significant negative association between log-transformed plasma phylloquinone and all-cause mortality after controlling for potential confounders (per 1 unit increase-OR: 0.79; 95% CI: 0.66, 0.95). Furthermore, the association of plasma
phylloquinone with risk of all-cause mortality differed by body mass index (BMI) (<25 kg/m2 compared with ≥25 kg/m2, P-interaction = 0.004). A significant trend of decreasing risk with increasing concentration of
phylloquinone was observed in participants with higher BMI (per 1 unit increase-OR: 0.71; 95% CI: 0.56, 0.90; P = 0.004). No significant correlation was found between phylloquinone and risk of all-cause mortality in those with BMI <25 kg/m2.
In Chinese patients with hypertension, there was a significant negative association between baseline plasma phylloquinone and all-cause mortality, especially among those with higher BMI.